Appoints Vice President of Regulatory Affairs and Vice President of
SAN MATEO, Calif., Oct. 9 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today the appointment of Susan Rinne as the Vice President of Regulatory Affairs and Russell Kawahata, Ph.D. as the Vice President of Pharmaceutical Science.
Anthony DiTonno, President & Chief Executive Officer, commented, "I am pleased to welcome both Susan and Russell. Susan brings to NeurogesX over 20 years of experience in the pharmaceutical regulatory affairs arena, with extensive expertise in regulatory operations and product registration for a broad range of therapeutic indications. Russell brings over two decades of experience in technical development and manufacturing, having supported late stage product development at major pharmaceutical organizations. Susan and Russell's appointment to our senior management team reflects our continued efforts to expand and strengthen our resources as we continue our efforts to gain regulatory approval of and commercialize our lead product candidate, NGX- 4010."
Susan Rinne previously served as Vice President of Regulatory Affairs at ALZA Corporation and as head of Global Labeling for West Coast Regulatory Affairs as part of Johnson & Johnson Pharmaceutical R&D Global Regulatory Affairs. Prior to that, Ms. Rinne served in various regulatory affairs roles at Syntex Corporation. Ms. Rinne received a Master of Science in Pharmacology and Toxicology and a Bachelors of Science from the University of California, Davis.
Dr. Kawahata previously served as Vice President, Technical Development and Operations at InterMune Corporation where he oversaw the development and manufacturing of clinical and commercial products. Previously, Dr. Kawahata was a General Manager at Soltec Operations, Australia. Prior to that, he served as Senior Director of Product Innovation and Pharmaceutical Science at Connetics Corporation, and served as Director of Process Development at Xoma Corporation and Systemix Inc. Dr. Kawahata earned a Ph.D. in Pharmacology and Environmental Toxicology from the University of California, Davis and a Bachelors of Science from the University of California, Berkeley.
NeurogesX' corporate headquarters has been relocated to facilitate the Company's expansion plans. The new address is 2215 Bridgepointe Parkway, Suite 200, San Mateo, CA 94404; Main Telephone Line (650) 358-3300.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX- 4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2007 PR Newswire.
All rights reserved